User login
Dr. Johanna Bendell picks the upcoming ASCO presentations she anticipates to be the most interesting in gastrointestinal research.
• 3504 Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population-based study.
• 3503 Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).
Dr. Johanna Bendell is the director, GI Oncology Research, and associate director, drug development unit, Sarah Cannon Research Institute, Nashville, Tenn.
Dr. Johanna Bendell picks the upcoming ASCO presentations she anticipates to be the most interesting in gastrointestinal research.
• 3504 Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population-based study.
• 3503 Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).
Dr. Johanna Bendell is the director, GI Oncology Research, and associate director, drug development unit, Sarah Cannon Research Institute, Nashville, Tenn.
Dr. Johanna Bendell picks the upcoming ASCO presentations she anticipates to be the most interesting in gastrointestinal research.
• 3504 Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population-based study.
• 3503 Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).
Dr. Johanna Bendell is the director, GI Oncology Research, and associate director, drug development unit, Sarah Cannon Research Institute, Nashville, Tenn.
